[
    [
        {
            "time": "2018-03-15",
            "original_text": "I'm kicking myself for not recommending these stocks",
            "features": {
                "keywords": [
                    "recommendation",
                    "stocks"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "I'm kicking myself for not recommending these stocks",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 2,
                "Impact": 2,
                "Duration": 1,
                "Entity_Density": 1,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates",
            "features": {
                "keywords": [
                    "Aduro",
                    "Q4",
                    "Earnings",
                    "Revenues",
                    "Estimates"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "What’s Expected for AstraZeneca’s or Eli Lilly’s EPS Growth",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "Eli Lilly",
                    "EPS",
                    "Growth"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "What’s Expected for AstraZeneca’s or Eli Lilly’s EPS Growth",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "Woburn's Abpro strengthens Chinese ties with immuno-oncology deal",
            "features": {
                "keywords": [
                    "Abpro",
                    "Chinese",
                    "immuno-oncology",
                    "deal"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Woburn's Abpro strengthens Chinese ties with immuno-oncology deal",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "Drug Price Debate: is Legislation Necessary?",
            "features": {
                "keywords": [
                    "Drug",
                    "Price",
                    "Debate",
                    "Legislation"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Drug Price Debate: is Legislation Necessary?",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 4,
                "Duration": 8,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "Will AstraZeneca or Eli Lilly Report More Revenue Growth?",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "Eli Lilly",
                    "Revenue",
                    "Growth"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Will AstraZeneca or Eli Lilly Report More Revenue Growth?",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates",
            "features": {
                "keywords": [
                    "United Therapeutics",
                    "Q4",
                    "Earnings",
                    "Sales",
                    "Beat",
                    "Estimates"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "Analysts’ Recommendations for AstraZeneca and Eli Lilly",
            "features": {
                "keywords": [
                    "Analysts",
                    "Recommendations",
                    "AstraZeneca",
                    "Eli Lilly"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Analysts’ Recommendations for AstraZeneca and Eli Lilly",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]